Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Revenue: ₺21,087 Mil (TTM As of Mar. 2026)


IST:GENIL Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS IST:GENIL
86 GF Score
Price ₺9.10
GF Value ₺8.17
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Gen Ilac Veglik Urunlerinayi ve Ticaret AS Revenue?

Gen Ilac Veglik Urunlerinayi ve Ticaret AS IST:GENIL +1.34% 86 Revenue is ₺21,087 Mil as of Mar. 2026. GuruFocus rates IST:GENIL with a GF Score™ of 86/100 and a GF Value™ of ₺8.17 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Gen Ilac Veglik Urunlerinayi ve Ticaret AS's revenue for the three months ended in Mar. 2026 was ₺6,624 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₺21,087 Mil. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Revenue per Share for the three months ended in Mar. 2026 was ₺1.47. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₺4.22.

Warning Sign:

Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Gen Ilac Veglik Urunlerinayi ve Ticaret AS was -0.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 14.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 59.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 8 years, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's highest 3-Year average Revenue per Share Growth Rate was 97.60% per year. The lowest was 14.80% per year. And the median was 76.20% per year.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS  (IST:GENIL) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS Revenue Related Terms


Gen Ilac Veglik Urunlerinayi ve Ticaret AS Revenue Historical Data

* Premium members only.

The historical data trend for Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gen Ilac Veglik Urunlerinayi ve Ticaret AS Revenue Chart

Gen Ilac Veglik Urunlerinayi ve Ticaret AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 2,501.35 10,639.34 11,769.21 19,294.44 19,181.45

Gen Ilac Veglik Urunlerinayi ve Ticaret AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,048.86 4,289.02 5,351.01 4,822.92 6,624.05

IST:GENIL vs ZTS, UTHR, VTRS: Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Revenue distribution charts can be found below:

* The bar in red indicates where Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Revenue falls into.


IST:GENIL
86GF Score
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS IST:GENIL
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gen Ilac Veglik Urunlerinayi ve Ticaret AS Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺21,087 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of ₺21,087 Mil mean?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) has a Revenue of ₺21,087 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Revenue too high?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current Revenue is ₺21,087 Mil. Overall, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Revenue compare to ZTS and UTHR?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Revenue of ₺21,087 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current Revenue is ₺21,087 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺8.17, compared to a current price of ₺9.10 — trading 11.4% above its estimated fair value. The current Revenue is ₺21,087 Mil. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL), the current Revenue is ₺21,087 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Overvalued in 2026?

Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock appears to be overvalued. The current stock price of ₺9.10 is trading 11.4% above its estimated GF Value™ of ₺8.17. GuruFocus considers Gen Ilac Veglik Urunlerinayi ve Ticaret AS to be Modestly Overvalued.

Key valuation signals for IST:GENIL:

  • Revenue: ₺21,087 Mil
  • GF Value™: ₺8.17 vs. price of ₺9.10 (11.4% above fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the IST:GENIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS Business Description

Address Mustafa Kemal Mahallesi 2119.Sk. No:3, Cankaya, Ankara, TUR, 06520
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
86GF Score

Get the complete analysis for IST:GENIL

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺9.10
Price
₺8.17
GF Value